Today: Today, Sprott Inc. Sold shares of Gilead Sciences Inc. (GILD)

Today, Sprott Inc. Sold shares of Gilead Sciences Inc. (GILD)

Sprott Inc. cut its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 9.8% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 69,000 shares of the biopharmaceutical company’s stock after selling 7,500 shares during the period. Sprott Inc.’s holdings in Gilead Sciences were worth $5,459,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Van Hulzen Asset Management LLC boosted its position in shares of Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares during the last quarter. Gemmer Asset Management LLC boosted its position in shares of Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 175 shares during the last quarter. Joel Isaacson & Co. LLC boosted its position in shares of Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares during the last quarter. Roble Belko & Company Inc boosted its position in shares of Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,035 shares during the last quarter. Finally, Pinkerton Retirement Specialists LLC boosted its position in shares of Gilead Sciences by 9,305.9% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,599 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 1,582 shares during the last quarter. Institutional investors own 76.65% of the company’s stock.

Gilead Sciences Inc. (NASDAQ:GILD) traded up 0.19% during mid-day trading on Friday, hitting $75.44. 3,068,606 shares of the stock traded hands. The company has a 50-day moving average of $74.56 and a 200 day moving average of $80.20. The firm has a market capitalization of $99.39 billion, a P/E ratio of 6.98 and a beta of 1.25. Gilead Sciences Inc. has a 1-year low of $71.39 and a 1-year high of $108.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.87 by $0.12. The firm had revenue of $7.40 billion for the quarter, compared to analysts’ expectations of $7.47 billion. Gilead Sciences had a net margin of 47.74% and a return on equity of 100.57%. The firm’s revenue for the quarter was down 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.22 EPS. On average, equities research analysts anticipate that Gilead Sciences Inc. will post $11.47 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $1.88 annualized dividend and a yield of 2.49%. Gilead Sciences’s payout ratio is presently 17.44%.

Several analysts have issued reports on GILD shares. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. Barclays PLC reaffirmed an “overweight” rating on shares of Gilead Sciences in a research report on Thursday, July 28th. Berenberg Bank started coverage on shares of Gilead Sciences in a research report on Thursday, September 22nd. They set a “buy” rating on the stock. Jefferies Group reaffirmed a “buy” rating and set a $91.00 price target on shares of Gilead Sciences in a research report on Thursday, September 22nd. Finally, Piper Jaffray Cos. set a $108.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, September 22nd. Ten equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $97.90.

In other Gilead Sciences news, Director John W. Madigan sold 105,000 shares of the business’s stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the sale, the director now owns 121,761 shares in the company, valued at approximately $9,115,028.46. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total value of $409,200.00. Following the sale, the executive vice president now owns 132,964 shares in the company, valued at approximately $10,881,773.76. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

About Gilead Sciences

Related posts

Leave a Comment